SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Frisell Thomas)
 

Search: WFRF:(Frisell Thomas) > (2015-2019) > Comparative effecti...

  • Frisell, ThomasKarolinska Institutet,Karolinska Institute (author)

Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA : Results from the nationwide Swedish register

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2019-01-21
  • Oxford University Press (OUP),2019
  • 11 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:aed6dab2-3c01-4dcc-be0b-b122170bb316
  • https://lup.lub.lu.se/record/aed6dab2-3c01-4dcc-be0b-b122170bb316URI
  • https://doi.org/10.1093/rheumatology/key433DOI
  • https://gup.ub.gu.se/publication/286000URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:142177964URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Objectives: Current guidelines rank abatacept, rituximab, tocilizumab and TNF-inhibitors (TNFi) as having equal effectiveness for the treatment of RA, at least as second line therapies. These recommendations are mainly based on meta-analysis of randomized controlled trials, with few direct drug-drug comparisons. Our objective was to compare the real-world absolute and relative effectiveness among RA patients starting any of the available biologic DMARDs (bDMARDs). Methods: We used the Swedish Rheumatology Register to identify patients with RA initiating TNFi, rituximab, abatacept or tocilizumab in 2010-2016 as first bDMARD (n = 9333), or after switch from TNFi as first bDMARD (n = 3941). National Swedish registers provided additional covariates and censoring events. Effectiveness was assessed 3 and 12 months after treatment start, as the proportion remaining on therapy and with EULAR Good Response, HAQ improvement >0.2, zero swollen/tender joints and CDAI remission. Adjusted differences were estimated with multivariable linear regression. Results: Patients starting non-TNFi (vs TNFi) as first bDMARD had a higher proportion remaining on drug and reaching most response outcomes as first bDMARD (1-year EULAR Good Response/HAQ improvement: TNFi 24.9/25.4%, rituximab 28.6/37.2%, abatacept 31.9/33.7%, tocilizumab 50.9/43.1%). After switch from a first TNFi, rituximab and tocilizumab, but not abatacept, were associated with significantly better response measures than TNFi (1-year EULAR Good Response/HAQ improvement: TNFi 11.6/16.1%, rituximab 24.8/33.2%, abatacept 13.1/17.5%, tocilizumab 34.1/29.4%). Differences remained significant after adjusting for potential confounders. Conclusion: Treatment outcomes among RA patients treated in Swedish clinical practice are in line with a superior effectiveness of non-TNFi bDMARDs, in particular tocilizumab and rituximab, compared with TNFi.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Dehlin, Mats,1968Gothenburg University,Göteborgs universitet,University of Gothenburg,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research(Swepub:gu)xdehma (author)
  • Di Giuseppe, DanielaKarolinska Institutet,Karolinska Institute (author)
  • Feltelius, NilsSwedish medical products agency (author)
  • Turesson, CarlLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Internal Medicine - Epidemiology,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-ctn (author)
  • Askling, JohanKarolinska Institutet,Karolinska Institute (author)
  • Ernestam, S.Karolinska Institutet (author)
  • Klareskog, L.Karolinska Institutet (author)
  • Nisell, R. (author)
  • Baecklund, E. (author)
  • Kastbom, A. (author)
  • Jacobsson, L. (author)
  • Lindqvist, E. (author)
  • d'Elia, H. F. (author)
  • Rantapaa-Dahlqvist, S (author)
  • Karolinska InstitutetKarolinska Institute (creator_code:org_t)
  • ARTIS Study Group

Related titles

  • In:Rheumatology (United Kingdom): Oxford University Press (OUP)58:8, s. 1367-13771462-03241462-0332

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view